PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-41.39%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
15.06%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
-38.60%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-38.60%
Both companies reducing total costs. Martin Whitman would check industry trends.
10.73%
Interest expense change of 10.73% while AVXL maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
38.60%
EBITDA growth 50-75% of AVXL's 66.34%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
38.60%
Operating income growth 50-75% of AVXL's 61.31%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
-122.72%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.20%
Tax expense reduction while AVXL shows 103.61% growth. Joel Greenblatt would examine advantage.
30.20%
Net income growth 50-75% of AVXL's 55.20%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
30.24%
EPS growth 50-75% of AVXL's 54.76%. Martin Whitman would scrutinize operations.
30.24%
Diluted EPS growth 50-75% of AVXL's 54.76%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.